2022

Alharbi, H. O., Hardyman, M. A., Cull, J. J., Markou, T., Cooper, S. T. E., Glennon, P. E., Fuller, S. J., Sugden, P. H. and Clerk, A. ORCID: https://orcid.org/0000-0002-5658-0708 (2022) Cardiomyocyte BRAF is a key signalling intermediate in cardiac hypertrophy in mice. Clinical Science, 136 (22). pp. 1661-1681. ISSN 0143-5221 doi: https://doi.org/10.1042/CS20220607

Clerk, A. ORCID: https://orcid.org/0000-0002-5658-0708, Meijles, D. N., Hardyman, M. A., Fuller, S. J., Chothani, S. P., Cull, J. J., Cooper, S. T. E., Alharbi, H. O., Vanezis, K., Felkin, L. E., Markou, T., Leonard, S. J., Shaw, S. W., Rackham, O. J. L., Cook, S. A., Glennon, P. E., Sheppard, M. N., Sembrat, J. C., Rojas, M., McTiernan, C. F., Barton, P. J. and Sugden, P. H. (2022) Cardiomyocyte BRAF and type 1 RAF inhibitors promote cardiomyocyte and cardiac hypertrophy in mice in vivo. Biochemical Journal, 479 (3). pp. 401-424. ISSN 0264-6021 doi: https://doi.org/10.1042/BCJ20210615

2021

Meijles, D. N., Cull, J. J., Cooper, S. T. E., Markou, T., Hardyman, M. A., Fuller, S. J., Alharbi, H. O., Haines, Z. H. R., Alcantara Alonso, V. ORCID: https://orcid.org/0000-0002-9782-2398, Glennon, P. E., Sheppard, M. N., Sugden, P. H. and Clerk, A. ORCID: https://orcid.org/0000-0002-5658-0708 (2021) The anti-cancer drug dabrafenib is not cardiotoxic and inhibits cardiac remodelling and fibrosis in a murine model of hypertension. Clinical Science, 135 (14). pp. 1631-1647. ISSN 0143-5221 doi: https://doi.org/10.1042/CS20210192

2019

Meijles, D. N., Zoumpoulidou, G., Markou, T., Rostron, K. A., Patel, R., Lay, K., Handa, B. S., Wong, B., Sugden, P. H. and Clerk, A. ORCID: https://orcid.org/0000-0002-5658-0708 (2019) The cardiomyocyte "redox rheostat": Redox signalling via the AMPK-mTOR axis and regulation of gene and protein expression balancing survival and death. Journal of molecular and cellular cardiology, 129. pp. 118-129. ISSN 1095-8584 doi: https://doi.org/10.1016/j.yjmcc.2019.02.006